Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital

Abstract

We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p = .001) and OS (p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.

Keywords:

• Peripheral T-cell lymphoma
• chemotherapy
• hematopoietic progenitor cell transplant

Acknowledgements

The authors acknowledge support from the National Institute for Health Research (NIHR) Royal Marsden Hospital/Institute of Cancer Research Biomedical Research Centre, London, UK.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1393671.

Additional information

Funding

D.C. has received research funding from Amgen, AstraZeneca, Bayer, Celgene, Merrimack, Medimmune, Merck Serono, and Sanofi. E.A.H. has received research funding from Bristol-Myers Squibb, Celgene, Merck KgA, travel expenses from Takeda and Janssen and participated in an advisory board for Janssen. I.C. has participated in advisory boards for Sanofi Oncology, Eli-Lilly, Bristol Meyers Squibb, MSD, Bayer, Roche, and Five Prime Therapeutics; received research funding from Janssen-Cilag, Sanofi Oncology, Merck-Serono, and Novartis; and received honoraria from Taiho, Pfizer, Amgen, and Eli-Lilly.